United States - English - NLM (National Library of Medicine)

appco pharma llc - doxepin hydrochloride (unii: 3u9a0fe9n5) (doxepin - unii:5asj6huz7d) - doxepin hydrochloride capsules are recommended for the treatment of: - psychoneurotic patients with depression and/or anxiety. - depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). - depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). - psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. the target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are no

United States - English - NLM (National Library of Medicine)

appco pharma llc - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine is indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients aged 8 to 18 years [see clinical studies (14.1)]. the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should periodically be re-evaluated [see dosage and administration (2.1)]. fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with obsessive compulsive disorder (ocd) [see clinical studies (14.2)]. the effectiveness of fluoxetine in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. therefore, the physician who elects to use fluoxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see dosage and administration (2.2)]. fluoxetine is indicated for the acute and maintenance treatment of binge-e

United States - English - NLM (National Library of Medicine)

appco pharma llc - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

United States - English - NLM (National Library of Medicine)

appco pharma llc - voriconazole (unii: jfu09i87tr) (voriconazole - unii:jfu09i87tr) - voriconazole 50 mg - voriconazole is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections: in clinical trials, the majority of isolates recovered were aspergillus fumigatus. there was a small number of cases of culture-proven disease due to species of aspergillus other than a. fumigatus [see clinical studies (14.1), and clinical pharmacology (12.4)]. [see clinical studies (14.2), and clinical pharmacology (12.4)] [see clinical studies (14.3), and clinical pharmacology (12.4)] [see clinical studies (14.4), and clinical pharmacology (12.4)] specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). therapy may be instituted before the results of the cultures and other laboratory studies are known. however, once these results become available, antifungal therapy should be adjusted accordingly. - voriconazole is contraindicated in patients with known hypersensitiv

United States - English - NLM (National Library of Medicine)

appco pharma llc - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg

United States - English - NLM (National Library of Medicine)

appco pharma llc - modafinil (unii: r3uk8x3u3d) (modafinil - unii:r3uk8x3u3d) - modafinil 100 mg

United States - English - NLM (National Library of Medicine)

appco pharma llc - doxazosin (unii: nw1291f1w8) (doxazosin - unii:nw1291f1w8) - doxazosin 1 mg

United States - English - NLM (National Library of Medicine)

appco pharma llc - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 3 mg

United States - English - NLM (National Library of Medicine)

appco pharma llc - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan 2.5 mg - zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. limitations of use - only use zolmitriptan if a clear diagnosis of migraine has been established. if a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan is administered to treat any subsequent attacks. - zolmitriptan is not indicated for the prevention of migraine attacks. - safety and effectiveness of zolmitriptan have not been established for cluster headache. zolmitriptan is contraindicated in patients with: - ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or coronary artery vasospasm including prinzmetal’s angina [see warnings and precautions (5.1)] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)] - his

United States - English - NLM (National Library of Medicine)

appco pharma llc - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 10 mg